PP_1170x120_10-25-21

Dr. Josh Bilenker

Lilly to acquire Loxo Oncology

Lilly to acquire Loxo Oncology

INDIANAPOLIS — Eli Lilly and Co. and Loxo Oncology, Inc. today announced a definitive agreement for Lilly to acquire Loxo Oncology for $235.00 per share in cash, or approximately $8.0 billion. Loxo Oncology is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers. The acquisition would be the largest and latest in a